Astellas' Phase III Front-Line AML Study Of Xospata Fails

Standard Of Care Has Shifted Since Trial's Initiation

 
• By Alaric DeArment

One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.

Acute myeloid leukemia a 3d-Render
Astellas said its Phase III study of Xospata in front-line AML did not show an overall survival benefit. • Source: Shutterstock

More from Clinical Trials

More from R&D